Table 2.

Molecule intervention of circadian clock under different stimulation.

Target	Molecule intervention	Stimulation	Phenotype	Ref.
REV-ERBα	Agonist-GSK4112	LPS	Decreased IL-6 in human MDMs, primary alveolar macrophages, and THP-1 cells; Reduced Cxcl11, Cxcl6, Il19, and Il10 in human MDMs	(Gibbs et al., 2012)
REV-ERB	Agonist-GSK4112/ Hemin	LPS	Reduced Il6 in THP-1	(Raghuram et al., 2007; Gibbs et al., 2012)
REV-ERBα	Antagonist-SR8278	viral-induced encephalitis	Reduced survival rate in mice; Increased CCL2 expression	(Gagnidze et al., 2016)
REV-ERBα	Antagonist-GSK1362	LPS	Reduced Il6, Ccl2, and G-csf in alveolar macrophages and decreased Il6 expression in BMDMs	(Pariollaud et al., 2018)
RORα and RORγ	Agonists-SR100, ursolic acid, SR2211, SR1555, or ML209	/	Inhibited development of Th17 cells and reduced inflammatory gene expression	(Kojetin and Burris, 2014)
REV-ERBα	Agonist-GSK4112/ SR9011	LPS	Inhibited microglial activation and reduced iNOS and COX-2 secretion and Il6 and Tnfα expression	(Nakazato et al., 2017; Guo et al., 2019)
REV-ERBα	Agonist-SR9011	/	Reduced phagocytosis, mitochondrial respiration, energy production, and metabolic-related gene expression in primary microglia	(Wolff et al., 2020)
REV-ERBα	Agonist-SR9011	TNFα	Decreased Tnfα, Il6, Ccl2, and Il1β, and increased Il10 in primary microglia	(Wolff et al., 2020)
REV-ERBα	Agonist-SR9009	LPS+ATP	Suppressed IL-1β and Il6 expression in primary microglia	(Griffin et al., 2019a)
REV-ERBα	Agonist-SR9009	LPS	Reduced Il6, Tnfa, and Il1b in primary astrocyte	(Griffin et al., 2019a)
REV-ERBα	Agonist-SR9009	LPS	Reduced Il6 and Ccl2 in hippocampus	(Griffin et al., 2019a)
REV-ERBα	Agonist-SR9011, SR9009, and SR10067	/	Increased wakefulness and reduced sleep and anxiety-like behavior in mice	(Banerjee et al., 2014)
REV-ERBα	Antagonist-SR8278	/	Induced Mania-like behavior	(Chung et al., 2014)
REV-ERBα	Antagonist-SR8278	fAβ1-42	Enhanced microglial phagocytosis and increased fAβ1-42 uptake by BV-2 cells	(Lee et al., 2020)